Executive summary. Europe's medical cannabis sector is expanding, but it remains fragmented and unusually difficult to measure. Germany is the dominant demand centre, Portugal is a major EU production and processing hub, and supply increasingly crosses several jurisdictions before reaching patients. The 2026 market is defined less by legalisation headlines than by prescribing channels, permit capacity, wholesale price pressure and the ability to turn GMP capability into repeat commercial supply.
Scope, method and data limitations
This report treats Europe as a collection of national medical markets rather than a single addressable market. Public data are uneven: Germany publishes import-permit information; some countries publish reimbursement or prescribing data; others publish licensing data without reliable patient volumes. Private market estimates frequently combine authorised medicines, unlicensed flower, magistral preparations and consumer CBD. ECI therefore distinguishes verified official figures, credible secondary estimates and directional interpretation.
Import authorisations are not identical to patient consumption. Material may be imported for processing, re-export, inventory or future sale. Likewise, licensed cultivation capacity is not a measure of realised production. The report avoids presenting a single continent-wide market value as a precise fact because the underlying definitions differ.
Germany: the demand centre and policy risk
Germany remains the central European medical cannabis market. The April 2024 reforms removed medical cannabis from the general narcotics scheduling framework and simplified prescribing. The result was a sharp increase in imports and telemedicine-led demand. Secondary analysis of BfArM data reports approximately 201 tonnes imported during 2025, compared with roughly 73 tonnes in 2024. That scale has attracted Canadian, Portuguese, Danish and other international suppliers.
Growth also triggered political scrutiny. In October 2025 the German cabinet approved proposals intended to require direct physician contact and restrict mail-order supply, citing a large rise in imports and concern about online prescribing. The exact commercial effect depends on the final legal implementation, but the direction is clear: Germany offers volume while remaining exposed to policy correction, price competition and pharmacy-channel controls.
Portugal: production and processing hub
Portugal has developed one of Europe's most important licensed cultivation and manufacturing clusters. INFARMED oversees cultivation, manufacture, import, export and product-market permissions. Portugal's strength is not domestic patient demand; it is climate, workforce capability, EU location and an established export ecosystem. Industry reporting indicates that exports accelerated strongly during 2025.
The Portuguese opportunity increasingly lies in processing, testing, packaging, release support and supply-chain integration—not only cultivation. Producers depending on one German buyer or a single bulk-flower specification remain vulnerable to price compression and permit delays.
United Kingdom, Denmark, Netherlands, Poland and emerging markets
The United Kingdom has a growing private prescription market but limited reimbursement and specialist-prescribing constraints. Denmark combines high pharmaceutical credibility with a smaller access programme and domestic production capability. The Netherlands retains a state-coordinated supply model through the Office of Medicinal Cannabis. Poland has become an important prescription market but experiences product availability and administrative variability. Switzerland is developing through medical access and research-based adult-use pilots, while France continues to move cautiously from experimentation toward a permanent framework.
These markets should be evaluated by channel, not just population. A smaller market with dependable pharmacy access, reimbursement and stable regulation may be more attractive than a larger market with severe price or policy volatility.
Supply structure and trade flows
Europe's supply structure is transnational. Canadian producers remain important upstream suppliers, Portugal operates as a major cultivation and processing base, and Germany is the dominant demand centre. Denmark, the Netherlands, North Macedonia, Colombia, Australia and other jurisdictions contribute specialised supply. The commercial chain may involve cultivation in one country, processing or EU batch release in another, importation into a third and pharmacy dispensing in a fourth.
| Role | Leading examples | Strategic issue |
|---|---|---|
| Demand centre | Germany, UK, Poland | Prescribing rules, reimbursement and pricing |
| EU production/processing | Portugal, Denmark, Malta | Utilisation, export permits and customer concentration |
| State-coordinated supply | Netherlands | Restricted producer and channel structure |
| Third-country supply | Canada, Australia, Colombia, North Macedonia | Import acceptance, GMP evidence and lead time |
Market segments and value migration
Commodity flower remains important, but margin is migrating toward differentiated products and services: stable cultivars, smaller-batch premium flower, extracts, oils, devices, testing, regulatory release, pharmacy services and patient platforms. Basic cultivation is increasingly exposed to oversupply and wholesale price compression. A European GMP certificate has commercial value only when paired with reliable output, accepted specifications, market access and customer demand.
Risks and outlook to 2030
The base case is continued medical-market growth with uneven national policy. Germany is likely to remain the largest market but may tighten prescribing and distribution. More countries may expand access, yet reimbursement will remain slower than legalisation. Wholesale flower prices are likely to remain under pressure unless products are differentiated by quality, genetics, availability or clinical utility.
The strongest businesses will have multiple markets, flexible product formats, disciplined working capital and pharmaceutical-quality systems. The weakest will remain dependent on speculative cultivation capacity, a single buyer or regulatory arbitrage.
| Scenario | Market effect | Likely winners |
|---|---|---|
| Managed expansion | Steady patient and product growth | Diversified GMP suppliers and pharmacy channels |
| German tightening | Slower telemedicine demand and inventory correction | Clinically integrated and reimbursed providers |
| Faster harmonisation | Lower duplication across countries | Pan-European manufacturers and distributors |
| Persistent fragmentation | High regulatory cost | Specialists with national expertise |
Frequently asked questions
How large is the European medical cannabis market?
No single authoritative figure exists because countries report different categories. Germany is clearly the largest market by import volume and commercial value.
Why are German import figures not the same as patient consumption?
Imports may include inventory, processing and later re-export, and permit data do not measure dispensing directly.
Why is Portugal important?
Portugal combines licensed cultivation, EU manufacturing capability and a developed export ecosystem.
Will flower remain the main product?
Flower will remain important, but value is likely to shift toward differentiated formats, services and patient access.
What is the biggest market risk?
Dependence on one country, buyer or prescribing channel.
What should investors verify?
Official licences, utilisation, actual sales, inventory age, accepted specifications and regulatory route.
Sources and further reading
- BfArM — medical cannabis and import information
- INFARMED — cannabis for medicinal purposes
- European Medicines Agency — cannabis-derived medicinal products
- EDQM — European Pharmacopoeia Cannabis flower monograph
- Reuters, 8 October 2025 — Germany moves to restrict online medical cannabis access
- Deemed Consulting, June 2026 — analysis of German import data
- Cannabis Europa, 2026 — European regulatory overview
Market figures and regulatory positions can change quickly. Confirm current official data and national law before relying on this publication for investment, medical, legal or operational decisions.